D.E. Shaw & Co
KRTX

D.E. Shaw & Co’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

D.E. Shaw & Co’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-52,600
Closed -$16.6M – 4868
2023
Q4 		$16.6M Hold
52,600
– – 0.01% 1052
2023
Q3 		$8.89M Buy
52,600
+10,000
+23% +$1.88M 0.01% 1367
2023
Q2 		$9.24M Buy
42,600
+4,900
+13% +$1.05M 0.01% 1402
2023
Q1 		$6.85M Buy
37,700
+16,200
+75% +$3.1M 0.01% 1680
2022
Q4 		$4.22M Buy
+21,500
New +$4.61M ﹤0.01% 2248

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

D.E. Shaw & Co's KRTX Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 19,131 shares — an estimated $6.06M sold.

D.E. Shaw & Co first reported a position in KRTX in Q4 2019 and held it in 11 quarters. The position peaked at $71.6M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • D.E. Shaw & Co reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 19,131 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $6.06M.
  • D.E. Shaw & Co first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • D.E. Shaw & Co's Karuna Therapeutics, Inc. Common Stock position peaked at $71.6M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.